Republican chairman wants FTC to review mergers of drug price negotiators

Republican chairman wants FTC to review mergers of drug price negotiators

House Energy and Commerce Committee Chairman Greg WaldenGregory (Greg) Paul WaldenFormer Ryan aide moves to K street Overnight Health Care — Presented by PCMA — Lawmakers pay tribute to John Dingell's legacy on health care | White House denies officials are sabotaging ObamaCare | FDA wants meeting with Juul, Altria execs on youth vaping House members hint at bipartisan net neutrality bill MORE (R-Ore.) on Friday requested a review of mergers by drug price negotiators, questioning whether the moves had driven up costs for patients.

Walden wrote to the Federal Trade Commission requesting a review looking at recent mergers of companies known as pharmacy benefit managers (PBMs), which negotiate prices with drug manufacturers.

In the letter, Walden said that while there is “conflicting information” on the impact of these mergers, he fears some companies could have “used their market power to try to increase their profits and that PBMs have encouraged higher list prices for prescription drugs that increase co-pays for patients.”

ADVERTISEMENT

The letter comes amid increased scrutiny of high drug prices. President TrumpDonald John TrumpBill Kristol resurfaces video of Pence calling Obama executive action on immigration a 'profound mistake' ACLU says planned national emergency declaration is 'clear abuse of presidential power' O'Rourke says he'd 'absolutely' take down border wall near El Paso if he could MORE has been calling out drug companies by name on Twitter, and his administration recently floated the possibility of allowing the importation of drugs to increase competition when there are price spikes.

The letter from Walden, which was also signed by GOP Reps. Gregg HarperGregory (Gregg) Livingston HarperCongress sends bill overhauling sexual harassment policy to Trump's desk Dems cry foul in undecided N.C. race Mississippi New Members 2019 MORE (Miss.) and Michael BurgessMichael Clifton BurgessHouse Dems to mull bills to overturn Trump ObamaCare actions Overnight Health Care: House set to vote on bill targeting drug companies for overcharging Medicaid | Dems press Trump officials on pre-existing conditions | Tobacco giant invests .8B in Canadian marijuana grower GOP struggles to find right Republican for Rules MORE (Texas), focuses more on PBMs, which have also come under scrutiny for a lack of transparency in setting prices.

Some drug pricing advocates, however, say the focus should be on drug companies that initially set the prices.